Caris Life Sciences Inc., a leading AI-driven company in precision medicine, announced the validation and extension of findings on tumor-infiltrating clonal hematopoiesis (TI-CH) through a study published in the New England Journal of Medicine. The study analyzed 3,255 matched tumor-blood NGS samples from Caris' extensive clinico-genomic database, focusing on patients with late-stage cancer. It confirmed the prevalence of TI-CH across solid tumors, with the highest incidence found in non-small cell lung cancer, affecting approximately 23% of patients. The study also highlighted that patients with TI-CH have a 30% higher risk of death compared to those without TI-CH. These findings underscore the critical role of clonal hematopoietic mutations in precision oncology, aiming to improve patient outcomes. Results from the study have already been presented and are available for viewing on the Caris Life Sciences website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA34836) on July 22, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.